Cognixion is a neurotechnology company developing non-invasive brain-computer interfaces for individuals with severe motor impairments. The company's flagship product, Cognixion ONE, is an augmented reality (AR) headset with integrated EEG that enables users with conditions like [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), cerebral palsy, and locked-in syndrome to communicate and control their environment through brain signals[@cognixion].
The development of non-invasive brain-computer interfaces represents a critical advancement in neurotechnology, providing communication solutions for patients who have lost the ability to speak or move due to neurodegenerative diseases. Cognixion ONE combines the accessibility of non-invasive EEG recording with the intuitive visual feedback of augmented reality, creating a unique platform for augmentative and alternative communication (AAC)[@wolpaw2004].
Communication is fundamental to human experience, and its loss represents one of the most devastating aspects of neurodegenerative disease. Conditions like ALS progressively destroy motor neurons, eventually robbing patients of their ability to speak, move, and even breathe independently. In the later stages of ALS, patients may retain full cognitive function while being completely locked within their bodies—a condition known as locked-in syndrome[@birbaumer2006].
Cognixion is a neurotechnology company developing non-invasive brain-computer interfaces for individuals with severe motor impairments. The company's flagship product, Cognixion ONE, is an augmented reality (AR) headset with integrated EEG that enables users with conditions like [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), cerebral palsy, and locked-in syndrome to communicate and control their environment through brain signals[@cognixion].
The development of non-invasive brain-computer interfaces represents a critical advancement in neurotechnology, providing communication solutions for patients who have lost the ability to speak or move due to neurodegenerative diseases. Cognixion ONE combines the accessibility of non-invasive EEG recording with the intuitive visual feedback of augmented reality, creating a unique platform for augmentative and alternative communication (AAC)[@wolpaw2004].
Communication is fundamental to human experience, and its loss represents one of the most devastating aspects of neurodegenerative disease. Conditions like ALS progressively destroy motor neurons, eventually robbing patients of their ability to speak, move, and even breathe independently. In the later stages of ALS, patients may retain full cognitive function while being completely locked within their bodies—a condition known as locked-in syndrome[@birbaumer2006].
Brain-computer interfaces (BCIs) offer a pathway to restore communication for these patients. By directly translating neural signals into computer commands, BCIs bypass damaged motor pathways entirely. The goal is to create a communication channel that depends only on cognitive function, not physical movement.
EEG-based BCIs have evolved significantly since their inception:
The Cognixion ONE represents a convergence of several technologies:
| Component | Specification | Function |
|-----------|--------------|----------|
| Form Factor | Wearable AR headset | Provides visual interface while accommodating EEG electrodes |
| EEG System | 8-channel dry-electrode | Records neural signals without conductive gel |
| Display | Transparent AR display | Shows visual feedback and communication interface |
| Audio | Integrated speakers | Provides auditory feedback and voice output |
| Processor | On-device AI chip | Performs real-time signal processing |
| Battery | Rechargeable lithium | Enables portable use |
Traditional EEG requires conductive gel applied to the scalp, which is time-consuming and uncomfortable for daily use. Cognixion's dry electrode technology addresses this limitation:
The Cognixion ONE employs a sophisticated signal processing pipeline:
The Cognixion ONE relies on [cortical oscillations](/mechanisms/cortical-oscillations) detected via EEG to decode user intent. These oscillations are rhythmic electrical patterns generated by synchronized neural activity:
When a user imagines moving, characteristic changes occur in sensorimotor cortex oscillations:
The classifier learns to associate these patterns with specific mental commands. With training, users can achieve accurate control of the interface.
The system leverages [neuroplasticity](/mechanisms/neuroplasticity) principles—the brain's ability to reorganize itself through experience. Through [BDNF](/proteins/bdnf-protein)-mediated [synaptic plasticity](/mechanisms/synaptic-plasticity), users can learn to modulate their brain signals for device control over time[@research2022].
This learning process involves:
The Cognixion ONE provides multiple communication modalities:
Beyond communication, the system enables environmental control:
The software offers extensive customization:
ALS is the primary target indication for Cognixion ONE. [ALS](/diseases/amyotrophic-lateral-sclerosis) involves progressive [excitotoxicity](/mechanisms/excitotoxicity) leading to motor neuron degeneration, eventually eliminating all voluntary movement while leaving cognition intact[@cognixiona].
Applications in ALS:
For individuals with severe motor impairments from cerebral palsy:
For patients with complete paralysis but intact cognition (locked-in syndrome):
For patients with brainstem injuries affecting motor function:
The technology also shows promise for:
| Jurisdiction | Status | Notes |
|-------------|--------|-------|
| FDA (USA) | Breakthrough Device Designation | Granted for ALS communication |
| EU | CE Mark Class IIa | Medical device certification |
| Canada | Health Canada clearance | In progress |
| Clinical Trials | Ongoing | US and Europe |
The FDA Breakthrough Device Designation is particularly significant, as it provides:
Several studies have validated the Cognixion ONE platform:
| Metric | Value | Notes |
|--------|-------|-------|
| Command Accuracy | 85-95% | Depends on training and user |
| Training Time | 15-30 minutes | For basic operation |
| Communication Rate | 10-20 words/minute | With predictive text |
| False Positive Rate | <5% | With adaptive thresholds |
| Feature | Cognixion ONE | BrainGate | Neuralink | Synchron |
|---------|--------------|-----------|-----------|----------|
| Invasiveness | Non-invasive | Invasive | Invasive | Minimally invasive |
| Modality | EEG+AR | Utah Array | N1 Chip | Stentrode |
| Primary Use | Communication | Communication | Motor | Communication |
| Mobility | Portable | Fixed | Implanted | Portable |
| Regulatory Status | FDA Cleared | Investigational | Phase 1 | Phase 1 |
| Setup Time | Minutes | Hours (surgery) | Hours (surgery) | Hours (surgery) |
The Cognixion BCI leverages several mechanisms directly relevant to neurodegenerative diseases:
[BDNF](/proteins/bdnf-protein) (Brain-Derived Neurotrophic Factor) supports neuronal survival and [synaptic plasticity](/mechanisms/synaptic-plasticity) during BCI training. BDNF signaling:
The brain's capacity to form new neural pathways enables users to learn BCI control. In neurodegenerative diseases:
The [motor cortex](/brain-regions/motor-cortex) is the primary neural target for motor intention decoding. Even in advanced neurodegenerative disease:
[Cortical oscillations](/mechanisms/cortical-oscillations) provide windows into neural network function:
[Excitotoxicity](/mechanisms/excitotoxicity) is relevant to ALS pathophysiology—understanding this mechanism informs BCI design for ALS patients:
Cognixion is actively developing next-generation capabilities:
The BCI communication market includes several competitors:
| Company | Technology | Invasiveness | Status |
|---------|------------|--------------|--------|
| Cognixion | EEG + AR | Non-invasive | Commercial |
| BrainGate | Utah Array | Invasive | Clinical trials |
| Neuralink | N1 Chip | Invasive | Phase 1 |
| Synchron | Stentrode | Minimally invasive | Clinical trials |
| g.tec | EEG | Non-invasive | Commercial |
| Emotiv | EEG | Non-invasive | Commercial |
Non-invasive solutions like Cognixion offer important advantages: safety, accessibility, and rapid deployment. While invasive systems may offer higher performance, the risk-benefit profile favors non-invasive approaches for many patients.
Cognixion ONE represents a significant advancement in non-invasive brain-computer interface technology. By combining dry-electrode EEG with augmented reality visualization, the system provides an accessible and intuitive communication tool for patients with severe motor impairments.
The platform addresses critical unmet needs in neurodegenerative disease care, particularly for ALS patients who lose the ability to communicate. With regulatory clearances in multiple jurisdictions and ongoing clinical evidence development, Cognixion ONE offers a practical solution that can be deployed today while continuing to improve through software updates and hardware refinements.
The integration of AI, the enhancement of neuroplasticity-based learning, and the expansion of applications position Cognixion as a leader in the transformation of BCI technology from laboratory research to clinical reality.